20 articles
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
Dr. Seheult explains how peaked T-waves on EKGs signal dangerous hyperkalemia and the emergency treatment that saves lives.
A feedforward ANGPT-TIE2 signaling loop amplifies PIK3CA-driven venous malformations, pointing to TIE2 inhibition as a more effective therapy than mTOR blockade.
A 330-patient multicenter RCT tests whether thymosin α1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
Long-term follow-up shows cliramitug safely depletes cardiac amyloid with improving heart structure, function, and quality of life.
Breakthrough anti-fibril depleters could revolutionize treatment for transthyretin amyloid cardiomyopathy, a deadly heart condition.
Breakthrough treatment works through multiple mechanisms beyond the lungs, enhancing oxygen delivery and muscle function.
A new NEJM editorial calls for broader surgical adoption of tranexamic acid, a proven blood-loss-reducing drug that remains underutilized worldwide.
CAR-M2 therapy successfully reversed kidney scarring in lab studies by eliminating harmful endothelial cells and promoting healing.
New cardiovascular research suggests where you live could impact how well heart treatments work for you.
The PRINCE trial investigators address scientific critiques of their landmark study on cardiac protection during noncardiac surgery.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
New editorial highlights advances in using stents to treat post-thrombotic syndrome, a chronic complication of blood clots.
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
Researchers propose targeting lymph node entry mechanisms to improve immune tolerance in cardiac transplant recipients, potentially reducing rejection.
Researchers tested injecting cardiac stem cells directly into heart arteries after heart attacks to promote healing and regeneration.
Advanced therapies like PCSK9 and ANGPTL3 inhibitors offer hope for kids with familial hypercholesterolemia when statins aren't enough.
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
Meta-analysis shows recaticimab dramatically reduces LDL cholesterol and other cardiovascular risk markers with manageable side effects.
Breakthrough study shows one epigenetic factor can transform cardiac fibroblasts into heart muscle cells, improving function after myocardial infarction.
